Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

X
Trial Profile

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; GS-9716 (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Aug 2023 Planned End Date changed from 1 May 2028 to 1 Jan 2027.
    • 29 Aug 2023 Planned primary completion date changed from 1 Mar 2027 to 1 Jan 2027.
    • 31 Jul 2023 Number of treatment arms have been reduced from 12 to 6 by the removal of 3 arms from part B and 3 arms from part C. One primary end-point is removed and patient enrollment is reduced. All the specific indication are removed from indications and Gemcitabine is removed from drugs.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top